Navigation Links
Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704 in ALS Development Program
Date:9/24/2007

S. prevalence is nearly 30,000 and the incidence is 1.2 per 100,000. Only a single drug has been approved for the treatment of ALS. Life expectancy after symptom onset is usually three to five years.

About Knopp Neurosciences Inc. (http://www.knoppneurosciences.com)

Knopp Neurosciences is a drug discovery and development company focused on delivering breakthrough treatments for neurological disorders through innovation, experience, and partnership. The company's lead product candidate is KNS-760704, an orally bioavailable small molecule in development for the treatment of ALS. Knopp's leadership includes experienced neuroscience drug development and discovery executives formerly associated with major pharmaceutical companies. Knopp's financing has been led Saturn Capital Inc. of Boston as placement agent and Saturn Partners II as lead funder.

This press release contains "forward-looking statements," including statements relating to Knopp's planned regulatory filings and clinical development programs for KNS-760704. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that KNS-760704 will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market the products. Knopp undertakes no obligation to update or revise any such forward-looking statement
'/>"/>

SOURCE Knopp Neurosciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Solstice Neurosciences Presents Escalating Dose Study at International Congress in Istanbul, Turkey
2. Malvern initiates European user group meetings for chemical imaging
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... July 28, 2015 Cumberland Pharmaceuticals Inc. (NASDAQ: ... second quarter 2015 financial results after the market closes ... live Internet webcast will be held on Tuesday, August ... the results. To participate in the call, ... international callers).  A rebroadcast of the teleconference will be ...
(Date:7/28/2015)... Corporation (NASDAQ: PMD ) today announced second quarter ... The Company also announced a quarterly dividend of $0.15 ... August 7, 2015 to be paid on August 18, ... consecutive quarterly dividend. The Company,s revenue for ... versus $7.7 million for the quarter ended June 30, ...
(Date:7/28/2015)... 28, 2015 /PRNewswire-USNewswire/ -- Kentucky,s ... doctor shopping after a 2012 law required providers to ... medications is yet more evidence that Californians need the ... Since Kentucky,s prescription drug abuse ... declined by 52 percent; opioid prescriptions to doctor-shopping individuals ...
Breaking Medicine Technology:Cumberland Pharmaceuticals To Announce Second Quarter 2015 Financial Results 2Psychemedics Corporation Announces Second Quarter Earnings 2Psychemedics Corporation Announces Second Quarter Earnings 3Psychemedics Corporation Announces Second Quarter Earnings 4Psychemedics Corporation Announces Second Quarter Earnings 5Psychemedics Corporation Announces Second Quarter Earnings 6Psychemedics Corporation Announces Second Quarter Earnings 7Psychemedics Corporation Announces Second Quarter Earnings 8Study Shows Requiring Prescription Drug Database Use Before Prescribing Powerful, Addictive Medications Critical In Ending Growing Epidemic, says Consumer Watchdog 2
... Calif., Oct. 21 Lumiphore Inc., a biotechnology ... use in high-value imaging, diagnostics, and therapeutics and ... that they have signed a global agreement on ... radiotherapeutics and companion diagnostics. Under the ...
... Sciences, Inc. (Nasdaq: CALP ) today announced ... ILMN ) for Caliper,s LabChip ® XT library ... platform. These systems are automated alternatives to traditional gel ... assessment. The LabChip platforms provide Genome Analyzer and HiSeq2000 ...
Cached Medicine Technology:Algeta and Lumiphore Announce Global Agreement for the Development of Targeted Alpha-Pharmaceutical Therapeutics 2Algeta and Lumiphore Announce Global Agreement for the Development of Targeted Alpha-Pharmaceutical Therapeutics 3Algeta and Lumiphore Announce Global Agreement for the Development of Targeted Alpha-Pharmaceutical Therapeutics 4Caliper Life Sciences Signs Co-Marketing Pact with Illumina to Improve Sequencing Workflows 2
(Date:7/29/2015)... ... July 29, 2015 , ... Employee Fiduciary, LLC announces the ... general contact information, website, types of plans administered, years in business, and credentials of ... have at least one plan with Employee Fiduciary. A search can be done by ...
(Date:7/29/2015)... ... ... TransFlip is an all new dynamic transition pack for FCPX, containing flipping ... are easy to apply and modify for any skill-level user. TransFlip includes custom bounce ... kinetic flipping panel animations are just a few clicks away. , TransFlip contains over ...
(Date:7/29/2015)... ... July 29, 2015 , ... Toronto native Douglas James ... Dr. Cottrell has been making predictions about the economy, politics, social issues, as ... these prognostications. He warns that extreme weather conditions and increased earthquake / volcanic ...
(Date:7/29/2015)... ... July 29, 2015 , ... The Woodlands and Spring Fit Body ... donating to worthy charitable causes each month. The new system will track each time ... each Check In at each facility, the boot camps will donate 20 cents to ...
(Date:7/29/2015)... Hoffman Estates, IL (PRWEB) , ... July 29, 2015 , ... ... can both benefit from two new products on Mercola.com: a vertical “garden tower” and ... – which can be squeezed into small corners on a porch, balcony, or rooftop ...
Breaking Medicine News(10 mins):Health News:Employee Fiduciary Launches Financial Advisor Directory 2Health News:Pixel Film Studios Releases FCPX Transition TransFlip for FCPX 2Health News:Author Warns Public to Prepare for Imminent Environmental Disaster 2Health News:Transforming Texan Lives and Bodies: Woodlands and Spring Fitness Boot Camps Commit to Multiple Charity Donations 2Health News:Transforming Texan Lives and Bodies: Woodlands and Spring Fitness Boot Camps Commit to Multiple Charity Donations 3Health News:Mercola.com Introduces NEW Garden Tower and Enhanced Mineral Solution for Healthy Plants 2
... ... Help Members Build Health Savings , ... Draper, UT (Vocus) April 27, 2010 -- HealthEquity, Inc. announced today that ... payment transaction processor for First HSA’s 43,000 health savings account (HSA) holders. , , ...
... ... 11:00 am, hundreds of participants including national, statewide and local leaders will gather at ... a nationwide health initiative created by First Lady Michelle Obama to fight childhood obesity ... arm of that campaign. , ...
... significant proportion of irritable bowel syndrome (IBS) patients treated ... four weeks of treatment, according to a new study ... journal of the American Gastroenterological Association (AGA) Institute. ... example, IBS symptom relief may be spared the ...
... ... the Best Treatment for Each Patient Based on State and Stage of Disease ... Pittsburgh, PA (PRWEB) ... Center (UPMC), announced that Space Coast Cancer Center (SCCC), Titusville, Fla., has selected ...
... scored highest in adherence to diet least likely to ... (HealthDay News) -- Eating a Mediterranean diet may help ... an ongoing study show. , "This diet emphasizes vegetables, ... wine and non-refined grain intake," study author Dr. Christy ...
... 80 ... Exposing Children to Diseases – In Response, Doggie-Bags® Offers Consumers a Solution to Dispose of ... Deerfield ... metric tons) of animal waste annually! Where does it all go? According to ...
Cached Medicine News:Health News:HealthEquity and First HSA Partner To Extend Industry Leadership 2Health News:MEDIA ADVISORY: Let's Move L.A. Inaugural Event and Launch Party. April 28th, 2010. 11am - 2pm. 2Health News:MEDIA ADVISORY: Let's Move L.A. Inaugural Event and Launch Party. April 28th, 2010. 11am - 2pm. 3Health News:Nonmedical treatment may rapidly relieve severe IBS symptoms 2Health News:Space Coast Cancer Center Selects Via Oncology™ Pathways to Advance Evidence-Based Cancer Care 2Health News:Space Coast Cancer Center Selects Via Oncology™ Pathways to Advance Evidence-Based Cancer Care 3Health News:Space Coast Cancer Center Selects Via Oncology™ Pathways to Advance Evidence-Based Cancer Care 4Health News:Doggie-Bags Addresses a Public Nuisance and a Serious Health Issue Caused by Exposure to Dog Waste 2Health News:Doggie-Bags Addresses a Public Nuisance and a Serious Health Issue Caused by Exposure to Dog Waste 3Health News:Doggie-Bags Addresses a Public Nuisance and a Serious Health Issue Caused by Exposure to Dog Waste 4
ApolipoproteinA-1 & B Calibrator...
CRP Calibrator...
Fructosamine controls level 3...
Drug controls sera available in three levels for the control of accuracy and percision for up to 18 analytes...
Medicine Products: